ReportWire

Tag: Medical Meetings

  • Conservative management vs. dialysis for preventing hospitalizations in patients with advanced kidney diseases and different ethnicities

    Conservative management vs. dialysis for preventing hospitalizations in patients with advanced kidney diseases and different ethnicities

    [ad_1]

    Highlights

    • Researchers have compared the impact of conservative management vs. dialysis on hospitalization outcomes in patients with advanced kidney disease across different races/ethnicities.
    • Results from the study will be presented at ASN Kidney Week 2022 November 3–November 6.

    Newswise — Orlando (November 5, 2022) — For some individuals with advanced kidney disease, dialysis may not be the optimal treatment strategy for their condition, and these patients may be better served with conservative non-dialytic management that focuses on quality of life and symptom control. Investigators recently examined the differential impact of conservative management vs. dialysis on hospitalization outcomes across varying racial/ethnic groups in a large national cohort of patients with advanced kidney disease. The research will be presented at ASN Kidney Week 2022 November 3–November 6. 

    In this study, the investigators compared hospitalization rates among 309,188 patients with advanced kidney disease who were treated with conservative management or dialysis over the period of 2007–2020. During follow-up, 55% of patients had 1 or more hospitalizations, and the most common causes of hospitalization in both groups were related to congestive heart failure/fluid overload, respiratory problems, or hypertension.

    In Non-Hispanic White, Non-Hispanic Black, and Hispanic patients, patients on dialysis had higher hospitalization rates than those who received conservative management, and patients who started dialysis early (transitioned to dialysis at higher levels of kidney function) demonstrated the highest rates across all age groups when compared with those who started dialysis late (transitioned to dialysis at lower levels of kidney function) or were treated with conservative management. Among Asian patients, those on dialysis also had higher hospitalization rates than those receiving conservative management, but patients who started dialysis late had higher rates than those on early dialysis, especially in older age groups.


    “There has been growing recognition of the importance of conservative non-dialytic management as an alternative patient-centered treatment strategy for advanced kidney disease. However, conservative management remains under-utilized in the US, which may in part be due to uncertainties regarding which patients will most benefit from dialysis vs. non-dialytic treatment,” said corresponding author Connie Rhee, MD, of the University of California, Irvine. “We hope that these findings and further research can help inform treatment options for patients, care partners, and providers in the shared decision-making process of conservative management vs. dialysis.”

     Study: “Impact of Race/Ethnicity and Age on Hospitalization Outcomes in Advanced CKD Patients Treated with Conservative Management vs. Dialysis”

    ASN Kidney Week 2022, the largest nephrology meeting of its kind, will provide a forum for nephrologists and other kidney health professionals to discuss the latest findings in research and engage in educational sessions related to advances in the care of patients with kidney diseases and related disorders.

    Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

     

     

     

     

    # # #

    [ad_2]

    American Society of Nephrology (ASN)

    Source link

  • Did having kidney disease and other conditions affect COVID-19 outcomes in different waves of the pandemic?

    Did having kidney disease and other conditions affect COVID-19 outcomes in different waves of the pandemic?

    [ad_1]

    Highlights

    • During 4 waves of the COVID-19 pandemic in New York City, the risk of severe COVID-19 was associated with pre-existing chronic kidney disease, as well as heart disease, diabetes, and hypertension.
    • The risk of acute kidney injury after developing COVID-19 was also associated with various pre-existing medical conditions.
    • Results from the study will be presented at ASN Kidney Week 2022 November 3–November 6.

    Newswise — Orlando (November 5, 2022) — Individuals with chronic kidney disease (CKD) are vulnerable to developing severe forms of COVID-19, and acute kidney injury is a common complication of COVID-19. A recent analysis examined the temporal effects of pre-existing CKD and other medical conditions on COVID-19 outcomes by waves throughout the pandemic. The findings will be presented at ASN Kidney Week 2022 November 3–November 6. 

    Investigators identified 64,246 COVID-19 cases during 4 waves at Columbia University Medical Center in New York City, with 8% being severe and 18% requiring hospitalization. Among the major findings:

    • The risk of severe COVID-19 was associated with pre-existing CKD, heart disease, diabetes, and hypertension in most waves; and lung disease, obesity, and cancer in at least one wave.
    • Acute kidney injury occurred in 49% of severe cases and 35% of hospitalized ones.
    • The risk of acute kidney injury was associated with heart failure, obesity, diabetes, and cancer in most waves; and CKD, coronary artery disease, hypertension, and stroke in one or two waves.

    “Pre-existing CKD was one of the most consistent clinical predictors of COVID-19 severity, complications, and poor outcomes across multiple pandemic waves,” said lead author Ning Shang, PhD. “Hospitals could include kidney function evaluation in patient populations as part of consideration for planning treatments and evaluating hospital capacities during future pandemic waves” added co-author Krzysztof Kiryluk, MD.

    Study: “Kidney Disease and COVID-19 Outcomes in the Temporal Analysis of Pandemic Waves”

    ASN Kidney Week 2022, the largest nephrology meeting of its kind, will provide a forum for nephrologists and other kidney health professionals to discuss the latest findings in research and engage in educational sessions related to advances in the care of patients with kidney diseases and related disorders.

    Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

     

     

    # # #

     

    [ad_2]

    American Society of Nephrology (ASN)

    Source link

  • The COVID-19 pandemic has had direct and indirect impacts on the mortality of patients on dialysis

    The COVID-19 pandemic has had direct and indirect impacts on the mortality of patients on dialysis

    [ad_1]

    Highlights

    • During the COVID-19 pandemic in 2020, mortality risk for both COVID-19–positive and other patients on hemodialysis fluctuated in line with two waves of the pandemic in the general population.
    • Compared with hemodialysis patients treated in 2019, the mortality risk of COVID-19–positive patients on dialysis persisted at much higher levels across 2020, whereas the mortality risk of other patients on dialysis was elevated slightly and mainly during the pandemic peak period.
    • Results from the study will be presented at ASN Kidney Week 2022 November 3–November 6.

    Newswise — Orlando (November 5, 2022) — New research has revealed elevated risks of death during the COVID-19 pandemic for both COVID-19–positive and other patients on hemodialysis compared with hemodialysis patients treated in 2019. The findings will be presented at ASN Kidney Week 2022 November 3–November 6.

    The study relied on data from 63,216 patients undergoing hemodialysis in 2019–2020 at NephroCare centers of 23 countries in European and Middle East countries.

    In line with two waves of the pandemic in the general population, two fluctuations of mortality risk were observed for both COVID-19–positive and other patients on hemodialysis (patients without a documented COVID-19 infection in Fresenius Medical Care’s electronic health record system). Compared with hemodialysis patients treated in 2019, the mortality risk of COVID-19–positive patients on dialysis persisted at much higher levels across 2020 (greater than 6.5-fold), whereas the mortality risk of other patients on dialysis was elevated slightly (less than 1.5-fold) and mainly during the pandemic peak periods.

    “The COVID-19 pandemic had direct and indirect impact on the mortality of hemodialysis patients,” said corresponding author Yan Zhang, PhD, of Fresenius Medical Care. “Potential reasons of the increased mortality among patients without confirmed COVID-19 diagnosis could be undertesting or healthcare system capacity constraints. Quantifying the magnitude of pandemic effects on patients with and without confirmed disease may benefit dialysis clinics to manage patients during critical events.” 

    Study: “COVID-19 pandemic effect on mortality of hemodialysis patients”

    ASN Kidney Week 2022, the largest nephrology meeting of its kind, will provide a forum for nephrologists and other kidney health professionals to discuss the latest findings in research and engage in educational sessions related to advances in the care of patients with kidney diseases and related disorders.

    Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

     

     

    # # #

     

                           

    [ad_2]

    American Society of Nephrology (ASN)

    Source link

  • Comparative Study of Two Heart Failure Drugs Finds No Difference in Outcomes

    Comparative Study of Two Heart Failure Drugs Finds No Difference in Outcomes

    [ad_1]

    Newswise — DURHAM, N.C. – In a head-to-head comparison of two so-called ‘water pills’ that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths, according to a large study led by Duke Health researchers.

    The study compared the diuretics torsemide and furosemide that were prescribed to patients with heart failure starting in the hospital setting. While prior data suggested a potential reduction in deaths among patients taking torsemide, the current study found no such benefit, providing clarity for both doctors and patients.

    “Given that the two different therapies provide the same effect on outcomes, we shouldn’t spend time switching patients from one to the other, and instead concentrate on giving the right dose and adjusting other therapies that have been proven to have long-term benefits,” said cardiologist Robert J. Mentz, M.D., chief of the heart failure section in the Division of Cardiology at Duke University School of Medicine and member of the Duke Clinical Research Institute.

    Mentz was lead author of the study, called TRANSFORM-HF and funded by the National Heart, Lung and Blood Institute. He presented the findings as a late-breaking clinical trial on Nov. 5 at the American Heart Association’s 2022 Scientific Sessions in Chicago.

    The study was designed as a direct comparison of loop diuretics, which are commonly prescribed to reduce the fluid buildup that causes swelling and breathing difficulties in patients with heart failure.

    Mentz and colleagues enrolled more than 2,800 patients hospitalized with heart failure. Participants were randomly assigned to receive either torsemide or furosemide, and doctors determined the dosing. The study group was diverse, with women comprising 37% of participants and Black patients comprising 34%.

    The main question was whether torsemide reduced patient deaths due to any cause over long-term follow-up (average of more than 17 months). The researchers found that death occurred in 373 of 1,431 study participants (26.1%) in the torsemide group and 374 of 1,428 patients (26.2%) in the furosemide group.

    A secondary outcomes analysis looked at deaths or hospitalizations within 12 months, and again found little difference, with death or hospitalization occurring in 677 patients (47.3%) in the torsemide group and 704 patients (49.3%) in the furosemide group.

    “This study has immediate clinical applications,” Mentz said. “Doctors spend a lot of time considering whether they will change from one diuretic to another, but there is no difference between the two for outcomes. This provides much-needed clarity. The insights from TRANSFORM-HF add to the evidence base that should help us improve patient care.”

    In addition to Mentz, study authors include Kevin J. Anstrom, Eric L. Eisenstein, Shelly Sapp, Stephen J. Greene, Shelby Morgan, Jeffrey M. Testani, Amanda H. Harrington, Vandana Sachdev, Fassil Ketema, Dong-Yun Kim, Patrice Desvigne-Nickens, Bertram Pitt, and Eric J. Velazquez.

    The study received support from the NHLBI (U01-HL125478, U01-HL125511, R01HL148354-04, R01HL154768-02).

     

    ###

     

    [ad_2]

    Duke Health

    Source link

  • Risks of kidney failure and death differ in Black and white veterans over time after chronic kidney disease onset

    Risks of kidney failure and death differ in Black and white veterans over time after chronic kidney disease onset

    [ad_1]

    Highlights

    • Among US veterans with chronic kidney disease (CKD), Black individuals had a higher risk of developing kidney failure compared with White veterans, and their risk was more pronounced in the early years after kidney disease onset.
    • The overall risk of death was similar in Black and White veterans, but Blacks had a higher risk early on, followed by a lower risk thereafter.
    • Results from the study will be presented at ASN Kidney Week 2022 November 3–November 6.

    Newswise — Orlando (November 4, 2022) — In an analysis of data on US veterans with chronic kidney disease (CKD), risks of kidney failure and death varied for Black compared with White veterans over time, with Black individuals being especially vulnerable in the early years after developing CKD. The research will be presented at ASN Kidney Week 2022 November 3–November 6.

    The study included 180,881 White and 32,187 Black veterans who developed CKD from 2003–2008 and were followed through 2018.

    During follow-up, the adjusted risk of kidney failure was 30% greater in Blacks than in Whites, but this difference was more pronounced over the early years of CKD onset (for example, a 38% greater risk in years 0–2) than at later years (only 8% greater risk in years 8–10). Despite an overall similar mortality risk after adjusting for major confounding factors, there was a greater risk of death for Blacks during the first 4 years of CKD onset, followed by a lower risk thereafter.

    These risk differences over time were consistent across subgroups, such as those with and without comorbidities including hypertension, diabetes, and cardiovascular diseases.

    “Black adults are particularly susceptible to kidney failure and death during the first several years of CKD onset. This result demands a stronger urgency for close evaluation in the earlier years of CKD to improve outcomes,” said corresponding author Guofen Yan, PhD, of the University of Virginia.

    Study: “Time-dependent risk differences in kidney failure and death between Black and White veterans following incident CKD”

    ASN Kidney Week 2022, the largest nephrology meeting of its kind, will provide a forum for nephrologists and other kidney health professionals to discuss the latest findings in research and engage in educational sessions related to advances in the care of patients with kidney diseases and related disorders.

    Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

     

    # # #

     

     

     

     

     

                           

    [ad_2]

    American Society of Nephrology (ASN)

    Source link

  • Long-Term Exposure to Air Pollution May Increase Kidney Disease Risk

    Long-Term Exposure to Air Pollution May Increase Kidney Disease Risk

    [ad_1]

    Highlights

    • Among adults with normal kidney function, exposure to higher concentrations of components of air pollution was linked with higher risks of later developing chronic kidney disease.
    • Compared with individuals with high genetic risk of developing kidney disease, those with high air pollution exposure and low genetic risk faced a higher risk of developing chronic kidney disease.  
    • Results from the study will be presented at ASN Kidney Week 2022 November 3–November 6.

    Newswise — Orlando (November 4, 2022) — Both genetic and environmental factors contribute to chronic kidney disease (CKD). New research assessed the interaction of air pollution and genetic factors on the development of CKD. The research will be presented at ASN Kidney Week 2022 November 3–November 6. 

    Investigators analyzed data from 350,994 participants without CKD at baseline in the UK Biobank. Exposure to higher concentrations of components of air pollution was linked with higher risks of developing CKD. Compared with individuals with high genetic risk of developing CKD, those with high air pollution exposure and low genetic risk faced a higher risk of developing CKD. 

    “Long-term exposure to air pollution may increase the risk of CKD, especially in those with low genetic risk,” the authors wrote.

    Study: “Air pollution, genetic factors, and the risk of incident chronic kidney disease: a prospective study of polygenic risk score analysis in the UK Biobank”

    ASN Kidney Week 2022, the largest nephrology meeting of its kind, will provide a forum for nephrologists and other kidney health professionals to discuss the latest findings in research and engage in educational sessions related to advances in the care of patients with kidney diseases and related disorders.

    Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

     

    # # #

     

     

     

     

     

                           

    [ad_2]

    American Society of Nephrology (ASN)

    Source link

  • American Neurological Association Announces New Leadership

    American Neurological Association Announces New Leadership

    [ad_1]

    Newswise — [MOUNT LAUREL, NJ, October 24, 2022] — The American Neurological Association (ANA), the professional organization representing the world’s leading academic neurologists and neuroscientists, has appointed Brenda Orffer, CAE, as its new Chief Executive Officer and Nadine Goldberg, PhD, MS, as Chief Program Officer.

    “We are delighted to welcome Brenda to the ANA and Nadine to a newly created role in the ANA,” said Frances E. Jensen, MD, FANA, FACP, president of the ANA and chair of the neurology department at the University of Pennsylvania. “The appointments of these accomplished professionals position our organization for continuity and strength as we look to the future.”

    Orffer will be responsible for overall operations of the ANA, including governance, budgeting, and financial oversight. She comes to the ANA from the Washington Health Care Association, where she served as executive vice president of the statewide nonprofit organization representing more than 500 assisted living and skilled nursing facilities.

    A graduate of Kent Christian College with a bachelor’s degree in theology, Orffer also served as mayor of the City of McCleary, Washington, and as a member of its city council. She currently volunteers as a member of the quality improvement committee at Summit Pacific Medical Center, giving her a perspective on the work that community hospitals do to improve the patient experience.

    “I’m excited to be part of an organization with a rich history and to help ensure its bright future,” Orffer said. “When I think about the discoveries being generated in neurology today, it’s just fascinating. I now have a front row seat to some of the most innovative technologies and advances in medicine.”

    Changing Hats

    Formerly executive director of the ANA, Goldberg will now set her focus on delivering the outstanding programming — both at the Annual Meeting and throughout the year — for which the ANA is known. As Chief Program Officer, she will play a key role in the development, strategy, and management of the organization as it supports academic neurologists and neuroscientists nationwide. She will oversee organizational partnerships and initiatives as well as all programming, including the ANA’s prestigious Annual Meeting. Building on her established work in professional education, she will continue to develop and manage membership programming that hones career skills and keeps members up-to-date on current issues, from online education and CME to the Research Careers Reimagined course for early-career professionals.

    Prior to joining the ANA in 2016, Goldberg held executive positions with the Juvenile Products Manufacturers Association and First Candle, a maternal and child welfare nonprofit. A graduate of the University of Greenwich with a bachelor’s degree in sociology, Goldberg earned a master’s degree in criminology from the University of Maryland Eastern Shore and a doctorate in medical sociology from Howard University.

    During her tenure as executive director, Goldberg stewarded the ANA’s continued growth, collaborating with industry leaders and cross-functional teams to develop innovative services and research that advanced the field of neurology. She expanded educational opportunities, cultivated participation of early-career academic neurologists, and implemented new awards programs to recognize and advance the work of ANA members from backgrounds that are under-represented in medicine.

    “It’s the ANA’s priority to ensure that our members have programming that supports them throughout their careers,” Goldberg said. “The ANA is driving a future of constant improvement and innovation across the fields of neurology and neuroscience. We must ensure that ANA members — including those who are in leadership positions, those just starting out, and those who are traditionally underrepresented — have the resources, support, and networks they need to make an impact.”

     

    About the American Neurological Association (ANA)

    From advances in stroke and dementia to movement disorders and epilepsy, the American Neurological Association has been the vanguard of research since 1875 as the premier professional society of academic neurologists and neuroscientists devoted to understanding and treating diseases of the nervous system. Its monthly Annals of Neurology is among the world’s most prestigious medical journals, and the ANA’s Annals of Clinical and Translational Neurology is an online-only, open access journal providing rapid dissemination of high-quality, peer-reviewed research related to all areas of neurology. The acclaimed ANA Annual Meeting draws faculty and trainees from the top academic departments across the U.S. and abroad for groundbreaking research, networking, and career development. For more information, visit www.myana.org or @TheNewANA1 on Twitter.

    [ad_2]

    American Neurological Association (ANA)

    Source link

  • Green eyeglasses reduce pain-related anxiety in fibromyalgia patients, study shows

    Green eyeglasses reduce pain-related anxiety in fibromyalgia patients, study shows

    [ad_1]

    Newswise — NEW ORLEANS — Wearing special green eyeglasses for several hours a day reduces pain-related anxiety and may help decrease the need for opioids to manage severe pain in fibromyalgia patients and possibly others who experience chronic pain, according to a study being presented at the ANESTHESIOLOGY® 2022 annual meeting.

    “Our research found that certain wavelengths of green light stimulate the pathways in the brain that help manage pain,” said Padma Gulur, M.D., lead author of the study and executive vice chair of Duke Anesthesiology and Duke Health, Chapel Hill, North Carolina. “There is an urgent need for additional treatments to reduce the use of opioids among patients with fibromyalgia and other types of chronic pain, and green eyeglasses could provide an easy-to-use, non-drug option.”

    Few alternatives to opioids — especially non-drug options — exist for patients with severe and chronic pain conditions such as fibromyalgia, which causes pain all over the body. Fibromyalgia affects about 4 million U.S. adults, according to the Centers for Disease Control and Prevention. 

    Pain and anxiety share similar biological mechanisms. Additionally, fear of pain exacerbates anxiety, often leading to increased opioid use, said Dr. Gulur. 

    The researchers studied 34 fibromyalgia patients who were randomized to wear various shades of eyeglasses four hours a day for two weeks: 10 patients wore blue eyeglasses, 12 wore clear eyeglasses and 12 wore green eyeglasses. Patients who wore green eyeglasses were four times more likely to have reduced anxiety than those in the other groups, which saw no reduction in anxiety. 

    “We found that although their pain scores remained the same, those who wore the green eyeglasses used fewer opioids, demonstrating that their pain was adequately controlled,” said Dr. Gulur. “We would recommend the green eyeglasses treatment for those with fibromyalgia and are studying patients with other chronic pain conditions to determine if it would be beneficial.”  

    The eyeglasses are specially formulated to filter a specific wavelength on the green light spectrum, said Dr. Gulur. She noted that most patients who wore the green eyeglasses reported feeling better and asked to keep wearing them.

     

    THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

    Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 55,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves. 

    For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/MadeforThisMoment. Join the ANESTHESIOLOGY® 2022 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES22.


    # # #

    [ad_2]

    American Society of Anesthesiologists (ASA)

    Source link

  • Cannabis use increases pain after surgery, study shows

    Cannabis use increases pain after surgery, study shows

    [ad_1]

    Newswise — NEW ORLEANS — Adults who use cannabis have more pain after surgery than those who don’t use cannabis, according to a study presented at the ANESTHESIOLOGY® 2022 annual meeting

    “Cannabis is the most commonly used illicit drug in the United States and increasingly used as an alternative treatment for chronic pain, but there is limited data that shows how it affects patient outcomes after surgery,” said Elyad Ekrami, M.D., lead author of the study and clinical research fellow of the Outcomes Research Department at Cleveland Clinic’s Anesthesiology Institute. “Our study shows that adults who use cannabis are having more — not less — postoperative pain. Consequently, they have higher opioid consumption after surgery.” 

    Researchers analyzed the records of 34,521 adult patients — 1,681 of them cannabis users — who had elective surgeries at Cleveland Clinic from January 2010 to December 2020. The cannabis users had used the drug within 30 days before surgery, while the other patients had never used cannabis. The patients who used cannabis experienced 14% more pain during the first 24 hours after surgery compared to the patients who never used cannabis. Additionally, patients who used cannabis consumed 7% more opioids after surgery, which the authors note was not statistically significant, but is likely clinically relevant.  

    “The association between cannabis use, pain scores and opioid consumption has been reported before in smaller studies, but they’ve had conflicting results,” Dr. Ekrami added. “Our study has a much larger sample size and does not include patients with chronic pain diagnosis or those who received regional anesthesia, which would have seriously conflicted our results. Furthermore, our study groups were balanced by confounding factors including age, sex, tobacco and other illicit drug use, as well as depression and psychological disorders.”

    Dr. Ekrami noted that additional research is needed to further define cannabis’ effects on surgical outcomes. “Physicians should consider that patients using cannabis may have more pain and require slightly higher doses of opioids after surgery, emphasizing the need to continue exploring a multimodal approach to post-surgical pain control,” he said.  


    THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS
    Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 55,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves. 

    For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/madeforthismoment. Join the ANESTHESIOLOGY® 2022 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES22.

    # # #

     

    [ad_2]

    American Society of Anesthesiologists (ASA)

    Source link

  • New Clinical Advances in Gastroenterology Presented at the American College of Gastroenterology’s 87th Annual Scientific Meeting

    New Clinical Advances in Gastroenterology Presented at the American College of Gastroenterology’s 87th Annual Scientific Meeting

    [ad_1]

    Newswise — Gastroenterologists and other health care professionals will convene at the Charlotte Convention Center in Charlotte, NC, for the premier clinical gastroenterology event—the American College of Gastroenterology’s 87th Annual Scientific Meeting and Postgraduate Course (ACG 2022) to review the latest scientific advances in gastrointestinal (GI) research, treatment of digestive diseases and clinical practice management.

    This year’s scientific presentations reveal significant findings and innovative technologies for the prevention, diagnosis and treatment of digestive diseases and serious GI-related health issues, including inflammatory bowel disease, bariatric surgery, colorectal cancer screening and prevention, liver disease, gastroesophageal reflux disease (GERD), GI bleeding, Barrett’s esophagus, as well as irritable bowel syndrome.

    • Can digital tools help physicians improve colonoscopy adherence rates?
    • What racial/ethnic disparities exist in the use of certain IBD medications?
    • Are pregnancy complications more likely among patients who have had bariatric surgery or took biologic medications?
    • Can virtual reality therapy help improve functional dyspepsia?
    • How has America’s fast-food fixation affected our liver health?
    • How can physicians combat health misinformation their patients find on social media?

    These are some of the intriguing clinical questions answered in the Newsworthy Abstracts selected by the ACG Public Relations Committee, with additional perspective on findings and explanation of what the clinical science means for patients provided by authors. Following the links below, reporters can explore these Newsworthy Abstracts and Author Insights and connect with these researchers for media stories. 

    Please note that all research presented at ACG 2022 is strictly embargoed until Sunday, October 23, 2022, at 12:00 pm Eastern Daylight Time.

    Helpful Links for Media Visit Press Info ACG Annual Scientific Meeting page of gi.org
    Explore ACG’s Press Room logistics, press releases, media advisories and links to author insights, commentary, and perspective on noteworthy clinical findings in gastroenterology and hepatology presented at the ACG 2022 Annual Scientific Meeting.
    [https://gi.org/media/press-info-scientific-meeting]

    Newsworthy Abstracts and Author Insights
    Nominated by the ACG Public Relations Committee, this group of abstracts features scientific findings that are innovative, noteworthy for the lay reader, relevant to those who suffer from common GI problems, and which represent a significant advancement in the diagnosis and treatment of GI diseases. The Committee aims to identify novel and thought-provoking abstracts which reinforce key public health messages, such as the importance of CRC screening, particularly for minority and at-risk populations, or which feature common GI problems in a new way.
    [https://gi.org/media/press-info-scientific-meeting/featured-science]  

    Featured Lectures
    Learn more about the featured lectures by renowned experts which will showcase innovative and challenging issues in clinical gastroenterology at ACG 2022
    [https://gi.org/2022/10/17/featured-lectures-at-acg-2022] 

    Navigating the Abstracts

    ACG 2022 Abstract Guide
    Look at pages 4-7 for the Abstract Award recipients. Look at pages 8-12 for the Presidential Poster Award recipients. ACG’s Presidential Posters are highly meritorious projects selected by the ACG Educational Affairs Committee. 

    Conference Platform
    Tip: Search all of the abstracts on the ACG 2022 Conference Platform:
    [https://www.eventscribe.net/2022/ACG2022/index.asp]

    • General Search: use the search bar at the top of the page. This search will pull any and every instance of an entered name or keyword(s).
    • Oral Papers: On the left sidebar, select “Presentations” and “Browse by Oral Abstracts.” The search will pull in all of the oral abstracts.
    • Posters: select the “Posters” option and in the new window that opens, browse by title, category (organ system), presenter, number, day and session, or award recipients using the left sidebar. Note: the ePoster Hall with final visual posters will open on Sunday, October 23, at 12pm ET.

    Media Interview Requests
    Press room and video recording facilities will be available on site at the Charlotte Convention Center. To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org. From Sunday, October 23, to Wednesday, October 26, in the ACG Press Room (W205 at the Charlotte Convention Center in Charlotte, NC). 

    About the American College of Gastroenterology
    Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of over 17,000 individuals from 86 countries. The College’s vision is to be the preeminent professional organization that champions the prevention, diagnosis, and treatment of digestive disorders, serving as a beacon to guide the delivery of the highest quality, compassionate, and evidence-based patient care. The mission of the College is to enhance the ability of our members to provide world class care to patients with digestive disorders and advance the profession through excellence and innovation based upon the pillars of Patient Care, Education, Scientific Investigation, Advocacy and Practice Management. www.gi.org

    Visit the ACG Website Media & Press section for all news, featured research, and expert insights related to the ACG 2022 Annual Scientific Meeting and Postgraduate Course. Follow ACG on Twitter, Facebook, LinkedIn, and Instagram, and share your live updates using #ACG2022.

    [ad_2]

    American College of Gastroenterology (ACG)

    Source link

  • Featured Lectures at the 2022 ACG Annual Scientific Meeting and Postgraduate Course

    Featured Lectures at the 2022 ACG Annual Scientific Meeting and Postgraduate Course

    [ad_1]

    Newswise — The featured lectures at the 2022 ACG Annual Scientific Meeting and Postgraduate Course showcase innovative and challenging issues in clinical gastroenterology. This year’s lectures highlight new approaches to inflammatory bowel disease, clinician-led research, optimizing colorectal cancer screening outreach, living with purpose, and the central role of the gut in overall health. All the 2022 featured lectures are at the invitation of ACG President Samir A. Shah, MD, FACG except for The American Journal of Gastroenterology Lecture which was invited by Co-Editors-in-Chief Jasmohan S. Bajaj, MD, MS, FACG and Millie D. Long, MD, MPH, FACG. Access is available for press to view livestreams of the lectures through the ACG 2022 Annual Scientific Meeting virtual platform.

    David Sun Lecture – The Two Most Important Days: Reflections on Lasting Happiness and Living With Purpose
    Sanjiv Chopra, MD
    Saturday, October 22, 10:00 am–10:30 am EDT
    Ways to achieve happiness and live your life’s purpose, no matter the challenges faced along the way. 

    President’s Address – ACG President, Samir A. Shah, MD, FACG, introduced by ACG President-Elect Daniel J. Pambianco, MD, FACG
    Monday, October 24, 9:00 am–9:30 am EDT

    The American Journal of Gastroenterology Lecture – The Transformative Power of Research Carried Out by Busy Clinicians
    Patrick S. Kamath, MD
    Monday, October 24, 3:05 pm–3:35 pm EDT
    How clinicians can participate in research that moves the fields of gastroenterology and hepatology forward.

    Edward Berk Distinguished Lecture – The Promise and Progress of New Approaches to Treating the Inflammatory Bowel Diseases
    Bruce E. Sands, MD, MS, FACG
    Tuesday, October 25, 10:05 am–10:30 am EDT
    Efficacy and safety of newer agents for IBD, and the potential for combination therapy and precision medicine approaches to treat Crohn’s disease and ulcerative colitis. 

    Emily Couric Memorial Lecture – Colon Cancer Screening: What Do We Need to Build and Who Will Come?
    Aasma Shaukat, MD, MPH, FACG
    Tuesday, October 25, 4:30 pm–5:00 pm EDT
    Current colon cancer screening tests and strategies to increase screening uptake in all populations. 

    David Y. Graham Lecture – Why Do All Diseases Start in the Gut?
    Emeran A. Mayer, MD
    Wednesday, October 26, 10:20 am–10:50 am EDT
    A better understanding of how the gut connectome translates microbial signals into health and disease.

     

    About the American College of Gastroenterology
    Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of over 17,000 individuals from 86 countries. The College’s vision is to be the preeminent professional organization that champions the prevention, diagnosis, and treatment of digestive disorders, serving as a beacon to guide the delivery of the highest quality, compassionate, and evidence-based patient care. The mission of the College is to enhance the ability of our members to provide world class care to patients with digestive disorders and advance the profession through excellence and innovation based upon the pillars of Patient Care, Education, Scientific Investigation, Advocacy and Practice Management. www.gi.org

    Visit the ACG Website Media & Press section for all news, featured research, and expert insights related to the ACG 2022 Annual Scientific Meeting and Postgraduate Course. Follow ACG on Twitter, Facebook, LinkedIn, and Instagram, and share your live updates using #ACG2022.

    [ad_2]

    American College of Gastroenterology (ACG)

    Source link

  • Radiation Therapy for High-Risk, Asymptomatic Bone Metastases May Prevent Pain and Prolong Life

    Radiation Therapy for High-Risk, Asymptomatic Bone Metastases May Prevent Pain and Prolong Life

    [ad_1]

    Newswise — SAN ANTONIO, October 23, 2022 — Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests. Results of the multicenter, randomized trial (NCT03523351) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

    The clinical trial findings suggest radiation oncologists may play a valuable role in treating widespread bone metastases even in the absence of symptoms. Palliative radiation has historically focused on reducing existing pain and other symptoms when a patient’s cancer is no longer considered curable. Investigators hoped to show that painful complications could be prevented by treating asymptomatic bone metastases with radiation and were surprised to find the benefits may extend beyond comfort.

    “It’s thought-provoking that radiation to prevent pain could potentially prolong life,” said Erin F. Gillespie, MD, lead author of the study and a radiation oncologist at Memorial Sloan Kettering Cancer Center in New York. “It suggests that treating to cure the cancer is not the only thing that can help people live longer.”

    The study arose from the observation that many patients hospitalized for painful bone metastases have evidence of these lesions on imaging scans several months earlier, Dr. Gillespie said. Although external beam radiation therapy is standard-of-care for painful lesions, it has not been used for asymptomatic ones outside of the oligometastatic setting; generally, patients remain on systemic therapy until lesions become symptomatic. Dr. Gillespie and her colleagues wanted to determine “if and when we might intervene before these symptoms occur to prevent hospitalizations and debility from cancer.”

    For the study, researchers identified 78 adults with a metastatic solid tumor malignancy and more than five metastatic lesions, including at least one asymptomatic high-risk bone lesion. Whether a lesion was high-risk was determined by its size (if it was 2 centimeters or more in diameter); its location in the junctional spine; whether it involved the hip or sacroiliac joint; or if it was in one of the long bones of the body, such as those found in arms and legs. Between all enrolled patients, there were a cumulative 122 bone metastases.

    Among study participants, the most common types of primary cancer were lung (27%), breast (24%) and prostate (22%). Participants were randomly assigned to receive standard treatment, which could include systemic treatment (such as chemotherapy or targeted agents) or observation, with or without radiation therapy to treat all of their high-risk bone metastases. Radiation doses varied but were typically low (i.e., not ablative). All patients were followed for at least 12 months or until they succumbed to their disease.

    The primary endpoint was to determine whether treating asymptomatic lesions could prevent skeletal-related events (SREs) – a common and often painful and debilitating complication of bone metastases. SREs include pain, fractures and compression of the spinal cord that requires surgery or radiation. They can contribute to a higher risk of death and higher health care costs.

    Researchers found that treating the asymptomatic lesions with radiation reduced the number SREs and SRE-related hospitalizations and extended overall survival, compared to people who received no radiation. At the end of one year, for patients on the radiation arm, SREs occurred in 1 of 62 lesions (1.6%), compared to 14 of 49 lesions (29%) for those receiving standard care (p<0.001). Significantly fewer patients in the radiation arm were hospitalized for SREs (0 vs. 4, p=0.045).

    After a median 2.4 years of follow-up, overall survival was significantly longer for patients who received radiation therapy, compared to those who did not (hazard ratio 0.50, 95% confidence interval 0.28-0.91, p=0.02). Median overall survival was 1.1 years for the 11 patients who experienced an SRE, compared to 1.5 years for the 67 patients who had no SREs.

    After the first three months, patients in the radiation arm reported less pain than those in the standard care arm (p<0.05), a trend that continued but was no longer statistically significant for the remainder of the study. There were no significant differences in quality of life between the two arms at any point in the study.

    Though it was not in the initial study design, Dr. Gillespie said the team performed an unplanned analysis of which lesions were most likely to cause SREs. While they expected to find those in the long bones might cause more fractures and pain, they found it was metastases in the spine that were most likely to cause subsequent pain, cord compression or fracture. However, the numbers are small and will require further evaluation to confirm.

    Treating those lesions with “even low doses of radiation seemed adequate to prevent the lesion from progressing and causing problems,” Dr. Gillespie said.

    Dr. Gillespie emphasized that because of the study’s small size, its findings, while hypothesis-generating, were not definitive and a larger study is needed to replicate and expand on these analyses. “Our trial results add to a growing field of study examining the potential of early supportive care, but they still need to be confirmed in a larger phase III trial,” she explained.

    She also said future research should seek to answer questions such as: “Does this apply to someone early in the course of their metastatic disease who may not have any symptomatic lesions? At what point would they benefit from intervention with radiation? There are many patients with multiple sites of metastases, but how do we identify those lesions that are most likely to become problematic?”

    “And, once we confirm this is the right thing to do,” she said, “how do we ensure patients who might benefit get access to this treatment?”

    ###

    Attribution to the American Society for Radiation Oncology (ASTRO) Annual Meeting is requested in all coverage. View the meeting press kit at www.astro.org/annualmeetingpress.

    See this study presented:

    • Prophylactic radiation therapy versus standard-of-care for patients with high-risk, asymptomatic bone metastases: A multicenter, randomized phase II trial (Abstract LBA 04)
    • News Briefing: Tuesday, October 25, 9:00 a.m. Central time. Details here.
    • Scientific Presentation: Clinical Trials Session, Sunday, October 23, 10:40 a.m. Central time, Henry B. Gonzalez Convention Center. Details here; email [email protected] for access.

     

    ABOUT ASTRO

    The American Society for Radiation Oncology (ASTRO) is the largest radiation oncology society in the world, with nearly 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and media center and follow us on social media.

     

    [ad_2]

    American Society for Radiation Oncology (ASTRO)

    Source link

  • Medical Physicist Consults with Patients Can Help Reduce Anxiety and Increase Satisfaction with Radiation Care

    Medical Physicist Consults with Patients Can Help Reduce Anxiety and Increase Satisfaction with Radiation Care

    [ad_1]

    Newswise — SAN ANTONIO, October 23, 2022 — Meeting with a medical physicist who can explain how radiation therapy is planned and delivered reduces patient anxiety and increases patient satisfaction throughout the treatment process, according to a new study published today in the International Journal of Radiation Oncology • Biology • Physics. Findings of the randomized, prospective phase III clinical trial also will be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

    “This study is a wake-up call for medical physicists that there are new ways we can add value to patient care,” said Todd F. Atwood, PhD, lead author of the study and an associate professor and Senior Associate Division Director of Transformational Clinical Physics at the University of California, San Diego. “It illustrates how care teams can partner more effectively with patients as they make their treatment decisions and navigate the radiation therapy process.”

    Medical physicists work with radiation oncologists to ensure complex treatment plans are properly tailored to each patient. They also develop and direct quality control programs to make sure treatments are delivered safely, including performing safety tests on the equipment used in a patient’s treatment.

    The new findings suggest that medical physicists also can supplement patient education and potentially improve patient outcomes by reducing patients’ treatment-related stress. “Patients increasingly want to be more involved with their care,” said Dr. Atwood. “They are looking for more information. Typically, they start by searching online, but what they’re finding is either non-specific or just too complex. They have unanswered questions, which often lead to confusion, stress and anxiety.”

    Prior studies have shown patient-related stress can negatively impact outcomes after radiation therapy. Dr. Atwood and his colleagues hope that by reducing stress and anxiety related to their treatment, this approach may also contribute to better patient outcomes.

    In this study, researchers randomized 66 patients seeking external beam radiation therapy into two treatment arms: one that would receive Physics Direct Patient Care (PDPC) prior to – and throughout – radiation treatment, and one that did not receive PDPC radiation therapy. Patients had different types of primary cancer, most commonly breast, gynecologic or prostate cancer, and most were receiving radiation therapy for the first time.

    In addition to traditional care, during which patients only discuss their treatment with their radiation oncologist, the PDPC group received two consultations prior to treatment with a medical physicist who explained the technical aspects of their care – how treatment is planned and delivered, how the radiation therapy technology works and “everything that goes into keeping them safe during treatment,” said Dr. Atwood. The medical physicist remained a resource for patients if additional questions arose at any point throughout the treatment process.

    Before interacting with patients, the five medical physicists participating in the study completed a patient communication training program that included radiation oncology specific lectures, role playing exercises, simulated patient interactions and analysis, and supervised physician-patient consults that included an analysis of those interactions.

    Changes in treatment-related anxiety, overall satisfaction with treatment and satisfaction with their understanding of the technical aspects of care were measured over the course of treatment using patient-reported questionnaires.

    Patients who received medical physicist consults had significant improvements in anxiety and both satisfaction metrics, compared to those who received treatment without the additional consults. Anxiety did not differ between the groups at baseline or following the simulation appointment, but it was lower, on average, for patients who got the medical physicist consults after the first treatment (30.2 vs. 37.6, on a 60-point inventory, p=0.027). By the end of treatment, however, the difference in average anxiety scores was no longer significant.

    To look more deeply at differences in anxiety between the groups, researchers looked specifically at the number of patients who reported high anxiety levels throughout treatment. While there were no significant differences in the proportion of high-anxiety patients at baseline, after the simulation appointment or after the first treatment, a substantial difference emerged by the end of treatment (12.5% vs. 38.9% reporting high anxiety, p=0.047).

    While the consults were beneficial for patients generally, Dr. Atwood said they may be particularly useful to patients who are more prone to anxiety. Among those receiving the additional consults, over the course of treatment, the percentage of patients reporting high anxiety levels dropped by more than half, from 31.3% to 12.5%.

    The greatest difference between the groups was seen in how satisfied patients were with their understanding of the technical aspects of their care. While there was no difference between the groups at baseline, the group that received an additional consult at the simulation appointment immediately expressed greater satisfaction with their technical understanding of care (6.2 vs. 5.1 on a 7-point scale, p=0.005). Technical satisfaction scores climbed for both groups throughout treatment, but they remained significantly higher for patients receiving additional consults, reaching 6.6 out of seven for that group, compared to 5.5 for the standard care group (p=0.002).

    Overall satisfaction was also significantly higher after the first treatment for patients who received physics consults (6.7 vs. 6.0 on a 7-point scale, p=0.014). While satisfaction rose for both groups following the first treatment, it remained significantly higher for the consult group until the end of treatment (6.9 vs. 6.2, p=0.001).

    Dr. Atwood said he was excited to see how long the benefits of supplemental consultation endured. “It has a lasting impact,” he said. “We’ve thought medical physics consults had great potential for years, but now we have a clearer understanding of how they positively impact the patient experience.”

    While other members of the care team could also be called upon to provide patients with a deeper understanding of their care, Dr. Atwood said he believes medical physicists were uniquely suited to the role because they were so familiar with the science driving the technology being used.

    “People don’t realize how personalized this therapy actually is. Medical physicists work behind the scenes to make sure this personalized treatment is both safe and effective. Our study indicates that there also can be a patient-facing role that will allow medical physicists to add more value to the patient experience” he said.

    ###

    Attribution to the American Society for Radiation Oncology (ASTRO) Annual Meeting is requested in all coverage.

    See this study presented:

    • Examining the impact of direct patient care for medical physicists: A randomized prospective phase III trial (Abstract 7)
    • News Briefing: Monday, October 24, 9:00 a.m. Central time. Details here.
    • Scientific Presentation: Clinical Trials Session, Sunday, October 23, 10:20 a.m. Central time, Henry B. Gonzalez Convention Center. Details here; email [email protected] for access.
    • Journal Citation: Atwood TF, Brown DW, Murphy JD, et al. Examining the Effect of Direct Patient Care for Medical Physicists: A Randomized Prospective Phase III Trial [published online ahead of print, 2022 Oct 24]. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2022.05.014

     

    ABOUT ASTRO

    The American Society for Radiation Oncology (ASTRO) is the largest radiation oncology society in the world, with nearly 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and media center and follow us on social media.

     

    [ad_2]

    American Society for Radiation Oncology (ASTRO)

    Source link

  • Systemic racism plays role in much higher maternal mortality rate among Black women

    Systemic racism plays role in much higher maternal mortality rate among Black women

    [ad_1]

    Newswise — NEW ORLEANS —  Black women have a 53% increased risk of dying in the hospital during childbirth, no matter their income level, type of insurance or other social determinants of health, suggesting systemic racism seriously impacts maternal health, according to an 11-year analysis of more than 9 million deliveries in U.S. hospitals being presented at the ANESTHESIOLOGY® 2022 annual meeting

    “This study is the most up-to-date and extensive study — factoring in various states, insurance types, hospital types and income levels — to determine that the much higher maternal mortality rate among Black women often cannot be attributed to differences in health, income or access to care alone,” said Robert White, M.D., M.S., lead author of the study and assistant professor of anesthesiology at Weill Cornell Medicine, New York. “Clearly there’s a need for legislation to improve access to health care throughout pregnancy and improve funding among safety-net hospitals. But it’s also essential that hospitals train their employees to provide culturally appropriate care, offer translation services and conduct implicit bias association testing.”

    Causes of maternal death include the development of blood clots, heart failure, postpartum hemorrhage (excessive blood loss) and pre-eclampsia (extremely high blood pressure). The U.S. maternal mortality rate of 17.3 deaths per 100,000 births is higher than any other developed nation, with a huge disparity gap between Black and white mothers. The Centers for Disease Control and Prevention defines maternal mortality as death during pregnancy, delivery or within one year of the end of the pregnancy. This study focused on maternal death during childbirth in a hospital. 

    The researchers analyzed 9.5 million deliveries occurring in hospitals between 2007 and 2018, based on State Inpatient Databases from California, Florida, Kentucky, Maryland, New York and Washington. Of those, 49,472 mothers (0.5%) died in the hospital or experienced injury to the heart, eyes, kidney, brain or other organ, including 0.8% of all Black women, 0.5% of all Hispanic women and 0.4% of all white women. The researchers determined that compared to white women, Black women had a 53% increased risk of dying in the hospital, even after adjusting for insurance type, hospital type, income and other societal factors. Hispanic women and white women had the same risk of dying in the hospital.

    “Physician anesthesiologists are leaders in quality, safety and perioperative medicine and are working very hard to help decrease racial differences through science and implementation of protocols that treat everyone the same — with a focus on those who are worse off to achieve health equity,” said Dr. White. “We not only provide pain management during childbirth, but our training in critical and emergency care help us to proactively handle complications, prevent death and ensure the health and safety of the mother and baby.” 

    Anesthesiologists are working on standardizing practices, which help reduce disparities. For example, the Society for Obstetric Anesthesia and Perinatology (SOAP) developed a protocol for enhanced recovery after cesarean delivery focusing on pain relief, movement, maternal-infant bonding, decreased opioid use and shorter length of stay. Anesthesiologists also have played a key role in the Alliance for Innovation on Maternal Health (AIM), a national data-driven quality improvement effort. This includes the development of patient safety bundles — a collection of evidence-informed, best practices to be implemented in all care settings, for every patient, in each episode of care — to improve outcomes. 

    Additionally, anesthesiologists have participated in state maternal mortality review committees to determine trends and system issues that can be improved, helped coordinate care for high-risk maternal disease and placenta implantation disorders, and organized and led simulations for obstetrical (OB) hemorrhage. This is of particular importance since the maternal mortality rate from OB hemorrhage is higher in Black women. Anesthesiologists have devised algorithms using point of care ultrasound (POCUS) that are especially helpful during OB hemorrhage and can be quickly used when a woman does not have a pulse to determine if there is activity in the heart.  

    The research in the abstract presented at ANESTHESIOLOGY 2022 was supported by a Foundation for Anesthesia Education and Research (FAER) Mentored Research Training Grant [FAER Grant ID:  MRTG-08-15-2021-White (Robert)].

     

    THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

    Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 55,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves. 

    For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/MadeforThisMoment. Join the ANESTHESIOLOGY® 2022 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES22.

    # # #

    [ad_2]

    American Society of Anesthesiologists (ASA)

    Source link

  • Opioid prescribing after surgery remains the same for seniors, but doses are lower, study shows

    Opioid prescribing after surgery remains the same for seniors, but doses are lower, study shows

    [ad_1]

    Newswise — NEW ORLEANS — Although there has been no decrease in the number of opioid prescriptions seniors receive after surgery, the doses of those prescriptions are lower, according to a study of more than a quarter million Canadian patients being presented at the ANESTHESIOLOGY® 2022 annual meeting.

    “While it’s good news that the doses in opioid prescriptions are being reduced, the fact that the actual number of opioid prescriptions filled has remained the same shows there is still an opportunity for improvement,” said Naheed Jivraj, MBBS, MS, FRCPC, lead author of the study and a critical care medicine fellow at the University of Toronto, Ontario. “That’s particularly true for procedures associated with low postoperative pain that can be effectively controlled with non-opioid medications such as acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs).”

    While opioids can be an important part of pain management after surgery, limiting their use, including by lowering the dose, is important since they can cause major side effects and lead to addiction, as well as a potentially deadly overdose.

    To assess trends in filling pain prescriptions in the week after surgery, the researchers studied the records of 278,366 patients representing all adults in Ontario older than 65 who had one of 14 surgical procedures between 2013 and 2019. The surgical procedures in the study included: thyroid removal, appendix removal, hernia repair, laparoscopic or open removal of the gallbladder, removal of the prostate, open-heart surgery, laparoscopic or open colon removal, laparoscopic vaginal or abdominal hysterectomy, removal of the breast, hip replacement and knee replacement. 

    They identified an increase in patients filling non-opioid prescriptions (e.g., acetaminophen or NSAID) from 9% in 2013 to 28% in 2019. They found most patients also continued to receive a prescription that contained an opioid — 76% in 2013 and 75% in 2019. However, the dose of the opioid prescriptions decreased, from an average of 317 MME (morphine milligram equivalent) in 2013 to an average of 260 MME in 2019. 

    Most patients undergoing procedures such as removal of the appendix or thyroid can get pain relief from acetaminophen or an NSAID; however, few patients who had these procedures filled prescriptions for those non-opioid alternatives, researchers noted.

    “Our study highlights how pain management practices are changing after surgery,” said Dr. Jivraj. “The increase in seniors filling non-opioid prescriptions and the lower opioid dose may reflect the development of surgery-specific prescribing guidelines and the increasing use of anesthesiologist-championed Enhanced Recovery After Surgery protocols and other programs that focus on improving patient outcomes.”

     

    THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

    Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 55,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves. 

    For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/MadeforThisMoment. Join the ANESTHESIOLOGY® 2022 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES22.

    # # #

    [ad_2]

    American Society of Anesthesiologists (ASA)

    Source link

  • Regular use of common cholesterol-lowering drug linked to reduction of COVID-19 severity, risk of death

    Regular use of common cholesterol-lowering drug linked to reduction of COVID-19 severity, risk of death

    [ad_1]

    NEW ORLEANS — Commonly used cholesterol-lowering statins may reduce the risk of death and severity of COVID-19 disease, suggests a study of more than 38,000 patients being presented at the ANESTHESIOLOGY® 2022 annual meeting.

    “While there is no ‘magic bullet’ to help patients who are very ill with COVID-19, statins decrease inflammation, which may help reduce the severity of the disease,” said Ettore Crimi, M.D., MBA, lead author of the study and professor of anesthesiology and critical care medicine, University of Central Florida, Orlando. “Results of our study clearly showed regular statin use is associated with reduced risk of death and improved outcomes in hospitalized COVID-19 patients.”

    The retrospective study is one of the most extensive of regular statin use in patients with COVID-19. Researchers analyzed the electronic medical records of 38,875 patients hospitalized for COVID-19 at 185 hospitals in the United States between Jan. 1 and Sept. 30, 2020. Of those patients, 30% regularly used statins to treat high cholesterol. Statin users had a 37% lower risk of dying from COVID-19 than those who didn’t use statins. In addition, regular statin users were significantly less likely to be discharged to hospice, be admitted to the intensive care unit (ICU) or develop blood clots. They also had shorter hospital stays and spent less time on a ventilator. 

    While COVID-19 itself causes inflammation, in some cases the immune system creates further inflammation by responding too aggressively to the infection. This extreme reaction causes much of the damage to the body, including difficulty breathing and damage to the lungs, kidneys, heart, brain and vascular system. The anti-inflammatory actions of statins “cool the process” so that the disease is not as severe, Dr. Crimi said.

    One in four Americans over the age of 40 take statins to lower their cholesterol and reduce their risk of heart attack, stroke and other cardiovascular diseases, according to the American Heart Association, making them one of the most commonly prescribed drugs.

    “This research illustrates the importance of evaluating medications that could be repurposed to help patients in ways other than their intended use,” said Dr. Crimi. “Our results suggest statins could be an additional cost-effective solution against COVID-19 disease severity and should be studied further.”

    THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

    Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 55,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves. 

    For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/MadeforThisMoment. Join the ANESTHESIOLOGY® 2022 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES22.

    # # #

    [ad_2]

    American Society of Anesthesiologists (ASA)

    Source link

  • Enhanced Recovery After Surgery program enables same-day hip and knee replacement surgeries during pandemic

    Enhanced Recovery After Surgery program enables same-day hip and knee replacement surgeries during pandemic

    [ad_1]

    Newswise — NEW ORLEANS — Adaptations to a program that helps ensure the best possible outcomes from surgery allowed eligible patients to receive their hip and knee replacement surgeries during the COVID-19 pandemic without spending the night in the hospital. The changes were so successful that they have been implemented permanently at the institution, according to a quality improvement study being presented at the ANESTHESIOLOGY® 2022 annual meeting.

    Championed by physician anesthesiologists, Enhanced Recovery After Surgery (ERAS) programs ease the effects of surgery and fast-track patient recovery.

    In 2019, Stony Brook Medicine in New York implemented an ERAS program for elective hip and knee replacement surgeries, with all patients spending at least one night in the hospital after the procedure. However, during the pandemic the team revised the ERAS program so that selective patients could have an outpatient procedure, meaning they didn’t spend the night in the hospital.

    The new ERAS protocol included: 

    • Developing a highly selective screening process to identify patients who would be good candidates for same-day surgery (i.e., relatively healthy, highly motivated with a good home-support system).
    • Using a shorter-acting spinal anesthetic. 
    • Hydrating patients before the procedure and restricting the fluids used during surgery.
    • Minimizing the use of urinary catheters to prevent infection.
    • Improving pain management by sending patients home on a non-opioid pain pump.
    • Providing home follow-up, including visits by nurses and physical therapists.

    “We found for many patients, same-day surgeries are a safe alternative to an extended hospital stay,” said Sunitha Singh, M.D., lead author of the quality improvement project and coordinator for the ERAS program at Stony Brook Medicine. “Education, prehabilitation and patient engagement are critical to the recovery process. Patients often feel more rested recovering at home in familiar surroundings, and we have made the ERAS changes permanent due to the high success.”

    Elective surgeries at Stony Brook Medicine were stopped during the peak of the pandemic (April-May 2020). The hospital implemented the new ERAS protocol beginning in June 2020 to provide continuity of care. 

    Over a one-year period, 152 patients had knee or hip replacement under the new program. Compared to patients who had the traditional ERAS protocol, patients in the new ERAS program stayed in the hospital an average of eight hours vs. an average of 1.7 days. No readmissions were reported. Currently, about 40% of the hospital’s hip and knee replacement patients participate in the same-day surgery ERAS program. 

    “Our findings demonstrate the adaptability of our health care system — including leveraging ERAS programs to respond to health care emergencies — while improving the quality of care,” Dr. Singh said.

     

    THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

    Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 55,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves. 

    For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/MadeforThisMoment. Join the ANESTHESIOLOGY® 2022 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES22.

    # # #

     

    [ad_2]

    American Society of Anesthesiologists (ASA)

    Source link

  • Opioid abuse decreases during pandemic, yet higher rates persist for sexual minorities

    Opioid abuse decreases during pandemic, yet higher rates persist for sexual minorities

    [ad_1]

    Newswise — NEW ORLEANS — Although opioid abuse in the U.S. is trending downward overall, it remains higher among non-heterosexuals than heterosexuals, according to an analysis of national survey data being presented at the ANESTHESIOLOGY® 2022 annual meeting.

    “This is the first analysis to look at the status of opioid abuse during COVID-19 in this population,” said Mario Moric, M.S., lead author of the research and a biostatistician at Rush University Medical Center, Chicago. “We thought the pandemic would prompt a spike in opioid abuse, but we are happy that this was not the case. However, the higher level of abuse among sexual minorities compared to heterosexuals is a concern. It underscores the need to focus on the risk factors and formulate strategies to reduce opioid abuse in this vulnerable population.”

    The researchers analyzed data collected through the annual National Survey on Drug Use and Health, which provides estimates of the prevalence of alcohol and drug use in the United States. More than 89,000 survey participants self-reported their sexual identity as heterosexual, homosexual or bisexual. The authors determined opioid abuse decreased between 2019 and 2020 among all three groups: from 3.5% to 3.2% for heterosexuals; 7.4% to 4.6% for homosexuals; and 10.3% to 7.6% for bisexuals. Overall, opioid abuse among adults 18 and older, regardless of sexual identity, declined by nearly 1 million, from 8 million adults in 2019 to 7.1 million adults in 2020.

    While opioid abuse went down, drug overdose deaths rose to an all-time high during the pandemic, according to the Centers for Disease Control and Prevention. 

    “We need to conduct more research to understand exactly why overdose deaths spiked during the pandemic,” Moric said. “It’s important to understand that our analysis measured the incidence of opioid abuse, and not the amount of consumption. It could be that while casual abuse declined, patients who tend to abuse opioids in higher amounts and more frequently used them at an even higher rate during the stress of the pandemic, increasing the rate of overdose deaths.”

    This analysis opens the door for future research to focus on identifying possible risk factors for these groups that will lead the development of programs aimed at reducing opioid abuse, the researchers noted. It also provides care teams with important insights that can impact their approach to treating vulnerable patient populations.

    “Clinicians need to be aware of the higher likelihood of recreational use of opioids among sexual minorities compared to non-LGBTQ populations,” Moric added. “With greater awareness of these disparities, we can foster a more compassionate understanding of these patients and provide the most appropriate care and education to address the issue and reduce the stigma.”

    THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

    Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 55,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves. 

    For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/MadeforThisMoment. Join the ANESTHESIOLOGY® 2022 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES22.

    # # #

    [ad_2]

    American Society of Anesthesiologists (ASA)

    Source link

  • Telemedicine reduces odds of no-show clinic visits by more than two-thirds for surgical patients

    Telemedicine reduces odds of no-show clinic visits by more than two-thirds for surgical patients

    [ad_1]

    Key takeaways 

    • Telemedicine significantly lowers likelihood of no-show clinic visits among surgical patients and follow-up care during the post-surgery period.   
    • Telemedicine is a convenient tool that can help improve healthcare for all patients, successfully increasing access among vulnerable populations.  

    Newswise — SAN DIEGO: Surgical patients who use telehealth services are much more likely to show up for their initial clinic visit or follow-up appointment during the post-surgery period than those who rely on in-person visits only. Research findings were presented at the Scientific Forum of the American College of Surgeons (ACS) Clinical Congress 2022. During the early months of the COVID pandemic, when everything shut down, telemedicine became an effective tool to reach patients. Building on those successes, more hospitals and clinics are implementing telehealth technology into their patient care practices.  

    Telehealth consists of an at-home interactive video and audio telecommunications system, allowing real-time connection between patients, nurses, and doctors. One major benefit to patients is that they avoid the trouble of travel to and from an appointment at a distant hospital or clinic. 

    “Low access to transportation is the number one reason for patient no-show visits.* Telemedicine is a feasible way for us to reach out to patients who would otherwise have a lot of barriers to access the healthcare system,” said lead study author Connie Shao, MD, a general surgery resident at the University of Alabama Birmingham.  

    “Maintaining routine healthcare such as clinic visits helps prevent emergent visits, which are typically at a point in time when a patient’s condition is much worse. Staying engaged with the healthcare system with timely care before and after surgery improves quality care, reduces costs for the patient, and helps ensure our patients are able to maintain a higher level of health.”  

    Even so, little is known about telemedicine use among surgical patients. 

    About the study  

    For this analysis, researchers evaluated the association between telemedicine use and patient no-show visits. They looked at data collected from seven clinics at the University of Alabama Birmingham among a diverse population of patients, with an average age of 60, undergoing all types of surgery between January 2018 and December 2021. 

    Researchers divided the patients into three categories:  

    1. a historical control of in-person visits from January 2018 to March 2020 
    2. a contemporary control of in-person visits from March 2020 to December 2021 
    3. a contemporary group of patients scheduled for telemedicine visits between March 2020 to December 2021  

    March 2020 was the start of the COVID-19 pandemic and, with that, a ramping up of telemedicine appointments. The three groups were compared for no-show visits.  

    Key findings 

    • Of the 553,475 total visits, 11.3% were no-shows. 
    • Most clinic visits were in the historical control (54.1%), compared with contemporary control (41.5%), and telemedicine visits—which included audio only and video (4.4%  for both types). 
    • The no-show rate was highest among in-person appointments (11.7%) compared to telemedicine visits (2.5%). 
    • Telemedicine was effective at reducing no-show visits. Of the small group of telemedicine visits, a multivariable adjusted analysis found a reduction in odds by 79% of no-show visits.  
    • No-show visits were also less common among older patients, those insured with Medicare, and the historical in-person visits from January 2018 to March 2020, compared with the contemporary in-person visits from March 2020 to December 2021.  
    • Disparities in no-show visits exist. For all visits, male patients were 12% more likely to not complete the appointments than women. Black patients, compared with white patients, were 68% more likely to be no-shows, and Asian patients were 32% more likely to be no-shows.  
    • Compared with private insurance, Medicaid patients were twice as likely to not complete the appointment. And patients from counties with a higher Social Vulnerability Index were 13% more likely to not complete the appointment. 

    Addressing the digital divide for patients  

    “Hopefully with the convenience of telemedicine now, the only bridge that we have to cross is the digital divide. We’ve partnered with a grassroots community program to train people in our community, especially older and more vulnerable people, on how to use telemedicine,” Dr. Shao said. “We can help keep these patients engaged in the healthcare system without having to take up their entire day to come and see us in the hospital.” 

    Giving all patients the option to use telehealth services may be of great benefit to surgical patients in the future. Dr. Shao is also developing best practice guidelines for the use of telemedicine for different surgical specialties during the post-surgery period.  

    “Telemedicine interventions such as training patients and offering more low-tech options, such as audio only, especially for patients who live far away, is an easier option. Some care is better than no care. And it’s far better for us to get some information at a telemedicine visit to take care of our patients in a timely interval than to wait to see the patient later on when they are sicker and have to be admitted to a hospital,” Dr. Shao said. “There is a time and place to use telemedicine. It certainly is an intervention worth considering to reduce no-show visits and to improve quality care across the board.” 

    The main limitation of the study is that the populations that are using telehealth technology are more likely, in general, to show up for a clinic visit (patients with better health literacy and access to the healthcare system disproportionately benefit from telemedicine).  Future studies that incorporate telemedicine training into patient visits will eliminate this confounding.  

    The study was supported by the ACS and the University of Alabama Birmingham Health Services and Outcomes Research Group.  

    Study coauthors are Marshall C. McLeod, PhD; Andy Hare, BS; Isabel C. Marques, MD; Lauren Gleason, MD, MSPH; Burkely P. Smith, MD; Eric L. Wallace, MD, FACS; and Daniel I. Chu, MD, FACS.   

    Citation: Shao C, et al. Telemedicine Associated with Decreased No-show Visits among Surgical Specialties, Scientific Forum, American College of Surgeons Clinical Congress 2022.    

    ________________________ 

    * Mieloszyk RJ, Rosenbaum JI, Hall CS, et al. Environmental Factors Predictive of No-Show Visits in Radiology: Observations of Three Million Outpatient Imaging Visits Over 16 Years, J Am Coll Radiol, 2016; 16 (4,B) 554-559.  

    # # #   

    About the American College of Surgeons 
    The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for all surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 84,000 members and is the largest organization of surgeons in the world. “FACS” designates that a surgeon is a Fellow of the American College of Surgeons. 

    [ad_2]

    American College of Surgeons (ACS)

    Source link

  • Study finds less expensive noninvasive test is an effective alternative to a more costly test for colorectal cancer screening

    Study finds less expensive noninvasive test is an effective alternative to a more costly test for colorectal cancer screening

    [ad_1]

    Key takeaways 

    • National guidelines suggest a fecal immunochemical test (FIT) can be used as the primary noninvasive screening modality for early-stage colorectal cancer, but a significant proportion of patients still receive a more expensive alternative test called Cologuard®. 
    • Data used for national screening guidelines has shown no difference between the two tests at detecting adenoma versus colorectal malignancy. 
    • These results align with previous studies out of Japan and the Netherlands examining FIT as an appropriate screening modality that is more cost effective than other types of noninvasive colorectal screening tests.  

    Newswise — SAN DIEGO: Commercially available noninvasive screening tests for colorectal cancer—a fecal immunochemical test (FIT) and the multi-target stool DNAtest (mt-sDNA; or Cologuard®)—are equally effective for screening patients with early-stage colorectal cancer. However, a FIT costs about one-fifth of the multi-target DNA test, according to new study results presented at the Scientific Forum of the American College of Surgeons (ACS) Clinical Congress 2022. 

    Pavan K. Rao, MD, a general surgery resident at Allegheny Health Network in Pittsburgh, Pennsylvania, presented study results looking at 117,519 people in the Highmark claims database who underwent colorectal screening in 2019. Highmark is a Blue Cross Blue Shield Association insurer in four Mid-Atlantic states.   

    From that group, the researchers identified 91,297 people who had noninvasive screening with either the fecal immunochemical test (FIT, n=45,487) or the DNA test (mt-sDNA, n=46,110) instead of having a routine colonoscopy.   

    Key findings  

    • Among the study population that underwent colorectal screening, 45,487 (38.7 percent) had one of two commercially available FIT tests and 46,110 (39.2 percent) had the mt-sDNA test.  
    • Patients who were screened with either test presented with early disease, staged from 0 to II, at similar rates: 59.5 percent for FIT and 63.2 percent for mt-sDNA test (p=0.77).  
    • Patients within the Allegheny Health Network Oncology Registry diagnosed with colorectal cancer were matched to their claims data to determine distribution of cancer stage.  If the noninvasive test indicated signs of early disease, patients were then referred for additional testing to confirm the findings.   
    • The total annual costs for the tests were $6.47 million—$1.1 million for a FIT, or about $24 per test, and $5.6 million for mt-sDNA, or about $121 per test. Costs were calculated using Medicare reimbursement rates. 

    Observations on study results  

    The study followed guidelines issued by the U.S. Preventive Services Task Force (USPSTF) in 2016 and updated in 2019. Since then, the guidelines were updated again in 2021.1 

    “Despite national guidelines suggesting that FIT be used as the primary noninvasive screening modality, we found that on review of our insurer’s claims data, a significant proportion of patients still receive a more expensive alternative test. There is substantial cost savings not only to our patients but to our health system with promoting appropriate use of noninvasive testing,” Dr. Rao said. 

    “There was no difference in the clinical stage at the time of diagnosis between the two tests, which again demonstrates the clinical equipoise maintained by switching to FIT,” Dr. Rao said of the variation between the two tests.  

    He added, “When you look at the national data for which the guidelines put forward, they found no difference between the two tests at detecting adenoma versus colorectal malignancy.”2 

    Cost savings without compromising care  

    The researchers determined that transitioning all noninvasive colorectal cancer screening to FIT would result in a $3.9 million savings annually in the study population.  

    “In the current state of healthcare, we are thinking ever more about efficiency and reduction in costs while maintaining patient outcomes, and not compromising the quality of care we provide,” Dr. Rao said. “I think a colorectal surgeon or any specialist who sees appropriate patients for colorectal cancer screening can use this data to provide recommendations of alternative screening tests to patients who primarily do not want to undergo colonoscopy. We cannot only say it is appropriate from a guideline standpoint, but we’re also reducing wasteful spending in health care by appropriately using the FIT.” 

     What makes this study unique is the methodology used to analyze the claims data, said study coauthor Casey J. Allen, MD, a surgical oncologist at Allegheny Health Network and an assistant professor at Drexel University College of Medicine, Pittsburgh. The researchers analyzed outcomes in the local health registry and then applied those outcomes to the claims database. “It’s not just the cost of the mt-sDNA test kit or the cost of the FIT kit multiplied by the number of members in the healthcare system,” Dr. Allen said. “It’s the full downstream costs depending on the rates of false-positive and false-negative tests and how much it costs to obtain a colonoscopy when that occurs. The cost of a screening colonoscopy in the database the researchers used was $635. 

    These results support previous studies out of Japan3 and the Netherlands4 that found FIT was more cost-effective than other types of noninvasive colorectal screening tests.  

    Study coauthors are Samantha Falls, DO, Stacey Shipley, BA, and Katie Farah, MD, of Allegheny Health Network, Wexford, Pennsylvania; and Patrick L. Wagner, MD, FACS, David L. Bartlett, MD, FACS, and Sricharan Chalikonda, MD, MHA, FACS, of Allegheny Health Network, Pittsburgh.  

    Dr. Rao and Dr. Allen have no disclosures to report. 

    Citation: Rao, PK et al. Comprehensive Cost Implications of Commercially Available Non-invasive Colorectal Cancer Screening Modalities: Results of A Large National Insurer Claims Database Analysis, Scientific Forum, American College of Surgeons Clinical Congress 2022.  

    ________________________ 

    1U.S. Preventive Services Taskforce. Final Recommendation Statement, Colorectal Cancer: Screening. Updated May 18, 2021. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening (.) 

    2Rex DK, Boland CR, Dominitz et al. Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016-1030. 

    3Sekiguchi M, Igarashi A, Sakamoto T, Saito Y, Esaki M, Matsuda T. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score. J Gastroenterol Hepatol. 2020 ;35(9):1555-1561.  

    4Lansdorp-Vogelaar I, Goede SL, Bosch LJW, et al. Cost-effectiveness of high-performance biomarker tests vs fecal immunochemical test for noninvasive colorectal cancer screening. Clin Gastroenterol Hepatol. 2018;16(4):504-512.e11.  

    # # # 

    About the American College of Surgeons 

    The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for all surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 84,000 members and is the largest organization of surgeons in the world. “FACS” designates that a surgeon is a Fellow of the American College of Surgeons. 

    [ad_2]

    American College of Surgeons (ACS)

    Source link